Cell therapy

Cell and gene therapy concept
#Cell and gene therapy #Cell therapy #Gene therapy #RNA

What are the challenges and advancements driving CGT drug development?

In this webinar you will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and Gerard Caelles, CBO at Splice Bio. Erik Wiklund will discuss how circular RNA is crucial to the development of next-generation cell and gene therapy products. Ali Pashazadeh will explore current barriers… Read More

Webinar date:
Sponsored by Benchling and Applied StemCell
#Webinars

Pluripotent stem cells
#Cell therapy #Neuroscience #Pluripotent stem cells #Society for Neuroscience #Stem cells

Neuroscience 2024: Leveraging human stem cells to treat diseases

Progress in stem cell technologies is advancing powerful new ways of studying and treating formerly intractable neurological and neuropsychiatric diseases. Several interwoven examples have been discussed at Neuroscience 2024, the annual meeting of the Society for Neuroscience. Over 40% of the global population lives with some… Read More

#News #Trending News

#Cell and gene therapy #Cell therapy #Gene therapy #RNA #Webinar

Webinar: Understand the challenges and advances driving CGTs

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News

Natural killer cells
#Cell therapy #Funding #Natural killer cells #NK:IO #Oncology

NK:IO progresses ovarian cancer natural killer therapy

Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million. The round included additional funding from UK Innovation Science and Seed Fund (UKI2S), managed by Future Planet Capital, Cambridge Angels and Cancer Research Horizons. The company says the funds will be used to… Read More

#Business & Investment #Cancer Research #News

Treg cells
#Cell therapy #Mouse models #Neuroinflammation #PolTREG #Preclinical investigations

Preclinical study to assess CAR-Treg cells for neuroinflammation

PolTREG has launched a preclinical study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. The study will measure the safety and efficacy of the therapy and data is anticipated by March 2025. PolTREG’s CAR-Treg cells are manufactured using the same technology… Read More

#News

#Cell and gene therapy #Cell therapy #Gene therapy #RNA

Webinar: Learn about the challenges for cell and gene therapies

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights vodcast: 24 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week we have seen… Read More

#News

#Biology #Cell and gene therapy #Cell therapy #Financing #Harvard Medical School #iPSC

Cell therapy company GC Therapeutics launches with $75m 

GC Therapeutics (GCTx) has launched with $75 million in total capital.  GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome (Transcription-Factor-ome), was invented and developed by scientists in the lab of Professor George Church at Harvard Medical School and the Wyss Institute.  It integrates synthetic biology, gene editing, cell engineering… Read More

#Business & Investment #News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights podcast: 23 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly… Read More

#News

#Cell and gene therapy #Cell therapy #Gene therapy #RNA

Webinar on the advancements driving cell and gene therapies

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (16-20 September) 

News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. The top stories: Study shows low… Read More

#News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Multiple sclerosis

New data support CAR-T therapy in neuroinflammatory diseases

Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases. The clinical trial results and case studies were presented in posters and a company-sponsored symposium at the 40th Congress of the European Committee for Treatment and Research in Multiple… Read More

#Editor's Choice #News

#Arsenal Biosciences #Cell therapy #Fundraising #Oncology #Solid tumours

Cell therapy developer ArsenalBio raises $325 million

Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours. The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by… Read More

#Business & Investment #News

Myeloma
#CAR-T #Cell and gene therapy #Cell therapy #FDA #Myeloma #Poseida Therapeutics #Roche

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma. The… Read More

#News #Regulatory

Natural killer cells
#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

Positive early data for Alzheimer’s natural killer cell therapy

NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD). An early independent review of the Phase I data shows that after three months treatment with… Read More

#Editor's Choice #News

Cell and gene therapy concept
#Cell and gene therapy #Cell therapy #Gene therapy #RNA

What are the advancements driving CGT drug development?

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News